Neuraminidase inhibitors for influenza complications

Chris Del Mar, Peter Doshi, Rokuro Hama, Mark Jones, Tom Jefferson, Carl Heneghan, Igho Onakpoya, Jeremy Howick

Research output: Contribution to journalLetterResearchpeer-review

1 Citation (Scopus)

Abstract

In their Comment (Aug 2, p 386),1 Jonathan Nguyen-Van-Tam and colleagues suggest that findings from our Cochrane review2 and a study of observational data3 are consistent. In our review, which was based on full clinical study reports of all manufacturer-sponsored randomised trials, we did not find evidence that neuraminidase inhibitors improve important outcomes of influenza, whereas the Roche-funded individual analysis of a subset of retrospective case reports suggested that neuraminidase inhibitors do have some beneficial effect.
Original languageEnglish
Pages (from-to)1260-1261
Number of pages2
JournalThe Lancet
Volume384
Issue number9950
DOIs
Publication statusPublished - 4 Oct 2014

Fingerprint Dive into the research topics of 'Neuraminidase inhibitors for influenza complications'. Together they form a unique fingerprint.

  • Cite this

    Del Mar, C., Doshi, P., Hama, R., Jones, M., Jefferson, T., Heneghan, C., Onakpoya, I., & Howick, J. (2014). Neuraminidase inhibitors for influenza complications. The Lancet, 384(9950), 1260-1261. https://doi.org/10.1016/S0140-6736(14)61761-X